EXPERIMENTAL OBJECTIVES: In vivo imaging of GLP-1 receptor-positive tissues may allow examination of physiologic and pathophysiologic processes. Based on the GLP-1 analog Exendin 4, we have developed a radiolabeled compound specifically targeting the GLP-1 receptor (DTPA-Lys40-Exendin 4). This work aims to detect GLP-1 receptor-positive tissues by biodistribution studies and in vivo small animal imaging studies. For in vivo imaging, a high-resolution multi-pinhole SPECT (single photon emission computed tomography) system was used in conjunction with an MRI (magnetic resonance imaging) system for image fusion. RESULTS: DTPA-Lys40-Exendin 4 can be labeled with 111In to high specific activity (40 GBq/micromol). The radiochemical purity reliably exceeded 95%. Using this compound for in vivo small animal imaging of rats and mice as well as for biodistribution studies, specific GLP-1 binding sites could be detected in stomach, pancreas, lung, adrenals, and pituitary. Receptor-positive tissues were visualized with a high-resolution SPECT system with a resolution of less than 1 mm. CONCLUSIONS: The new technique using DTPA-Lys40-Exendin 4 allows highly sensitive imaging of GLP-1 receptor-positive tissues in vivo. Therefore, intra-individual follow-up studies of GLP-1 receptor-positive tissue could be conducted in vivo.
EXPERIMENTAL OBJECTIVES: In vivo imaging of GLP-1 receptor-positive tissues may allow examination of physiologic and pathophysiologic processes. Based on the GLP-1 analog Exendin 4, we have developed a radiolabeled compound specifically targeting the GLP-1 receptor (DTPA-Lys40-Exendin 4). This work aims to detect GLP-1 receptor-positive tissues by biodistribution studies and in vivo small animal imaging studies. For in vivo imaging, a high-resolution multi-pinhole SPECT (single photon emission computed tomography) system was used in conjunction with an MRI (magnetic resonance imaging) system for image fusion. RESULTS:DTPA-Lys40-Exendin 4 can be labeled with 111In to high specific activity (40 GBq/micromol). The radiochemical purity reliably exceeded 95%. Using this compound for in vivo small animal imaging of rats and mice as well as for biodistribution studies, specific GLP-1 binding sites could be detected in stomach, pancreas, lung, adrenals, and pituitary. Receptor-positive tissues were visualized with a high-resolution SPECT system with a resolution of less than 1 mm. CONCLUSIONS: The new technique using DTPA-Lys40-Exendin 4 allows highly sensitive imaging of GLP-1 receptor-positive tissues in vivo. Therefore, intra-individual follow-up studies of GLP-1 receptor-positive tissue could be conducted in vivo.
Authors: Bernhard Aigner; Simone Renner; Barbara Kessler; Nikolai Klymiuk; Mayuko Kurome; Annegret Wünsch; Eckhard Wolf Journal: J Mol Med (Berl) Date: 2010-03-26 Impact factor: 4.599
Authors: Maarten Brom; Lieke Joosten; Wim J G Oyen; Martin Gotthardt; Otto C Boerman Journal: Contrast Media Mol Imaging Date: 2012 Mar-Apr Impact factor: 3.161
Authors: S Ueberberg; D Ziegler; W Schechinger; J W Dietrich; S Akinturk; H H Klein; S Schneider Journal: Diabetologia Date: 2010-04-06 Impact factor: 10.122
Authors: Amy C Kelly; Leah V Steyn; Jenna P Kitzmann; Miranda J Anderson; Kate R Mueller; Nathaniel J Hart; Ronald M Lynch; Klearchos K Papas; Sean W Limesand Journal: Xenotransplantation Date: 2014-05-07 Impact factor: 3.907
Authors: Sandra Ueberberg; Juris J Meier; Carmen Waengler; Wolfgang Schechinger; Johannes W Dietrich; Andrea Tannapfel; Inge Schmitz; Ralf Schirrmacher; Manfred Köller; Harald H Klein; Stephan Schneider Journal: Diabetes Date: 2009-07-10 Impact factor: 9.461